The measles outbreak that began at Disneyland is spreading across California and beyond, and it's reigniting a heated debate over the anti-vaccination movement.
In July last year, GlaxoSmithKline submitted its malaria vaccine, RTS,S, for regulatory review by the European Medicines Agency. Because there are no existing malaria vaccines, Glaxo says that a vaccine to be used "alongside other measures such as bed nets and anti-malarial medicines" would be an advance in malaria control. However, a new study published Monday might have GSK rethinking the bed nets.
Johnson & Johnson may have been third to bring its Ebola vaccine to human trials, but it is about to pick up the pace on developing its candidate, thanks to a €100 million grant from a European public-private partnership.
The affordable meningitis A vaccine, MenAfriVac, has been given to millions of people in Africa's so-called "meningitis belt," and is about to be administered to even more. The World Health Organization approved the shot, previously approved for people aged one to 29, for use in the routine immunization of infants less than one year old in sub-Saharan Africa.
A powdered measles vaccine could mean a cheaper option for the developing world that eliminates storage, contamination and waste challenges. And researchers now have one that looks safe in Phase I.
Just days after GlaxoSmithKline and the NIH's National Instite of Allergy and Infectious Diseases announced Phase I success for their investigative Ebola vaccine, Merck and NewLink Genetics have their own positive news to report.
The race for an Ebola vaccine is ramping up with positive Phase I data from an experimental vaccine made by GlaxoSmithKline and the NIH's National Institute of Allergy and Infectious Diseases. And thanks to those results, larger trials could be on the way soon.
To scale up production of its Ebola vaccine, NewLink Genetics is going to need some manufacturing help. And for that, it's turning to vaccine giant Merck.
Themis Bioscience and the Institut Pasteur have good news to report from a Phase I trial of their Chikungunya fever vaccine candidate. And the pair thinks its successful results just might lead to advances in other diseases, too.
As Pfizer's Trumenba rolls out in the U.S., it may get a head start on Novartis' Bexsero, which is still awaiting FDA approval. But the drug giant still doesn't yet have what it needs to build a considerable lead: a recommendation from the CDC's Advisory Committee on Immunization Practices.